



OXIS International

*Anthony Cataldo
President and Chief
Executive Officer*



Forward Looking Statements

Except for the historical information contained herein, the matters discussed in this presentation include forward-looking statements. Such statements in this presentation, including those regarding future financings necessary to acquire BioCheck, anticipated efficiencies arising from the acquisition, future product launch dates, are only predictions and reflect current beliefs and expectations of the Company. Actual results may differ materially from those predicted in such forward-looking statements due to the risks and uncertainties inherent in the Company's business, including, without limitation, risks and uncertainties in obtaining and maintaining regulatory approval, market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing, and the Company's ability to obtain additional financing to support its operations. We refer you to the risks and factors detailed from time to time in the Company's reports with the SEC, including but not limited to the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. The Company undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.



■ OVERVIEW

- Ergothioneine is one of the more powerful antioxidants in the highly lucrative nutraceuticals market
- License agreement with Alteon Inc. for ALT-2074
- Shares listed on OTCBB (OXIS)
- Shares out: ~ 47 million



■ 2007 FINANCING

- Private placement of secured convertible debentures and warrants
- Gross proceeds of \$1.7 million
- Use of proceeds
 - Working capital
 - Implementation of marketing campaign
 - Repayment of \$600,000 in debt
 - Regulatory studies/submissions



Company Management

- Anthony Cataldo
 - *Chief Executive Officer, Director*
- Michael Handelman
 - *Financial Consultant*
- William John Reiningger
 - *VP of Investor Relations, Director*

Cataldo Bio

- Anthony J. Cataldo served as Chief Executive Officer and Chairman of VoIP, Inc (OTC BB:VOII) from September 2006 through April 2008. During the past five (5) years, Mr. Cataldo has served as non-executive chairman of the board of directors of BrandPartners Group, Inc. (OTC BB:BPTR), a provider of integrated products and services dedicated to providing financial services and traditional retail clients with turn-key environmental solutions from October 2003 through August 2006. Mr. Cataldo also served as non-executive co-chairman of the board of MultiCell Technologies, Inc. (OTC BB: MUCL), a supplier of functional, non-tumorigenic immortalized human hepatocytes from February 2005 through July 2006. Mr. Cataldo has also served as executive chairman of Calypte Biomedical Corporation (AMEX: HIV), a publicly traded biotechnology company, involved in the development and sale of urine based HIV-1 screening tests from May 2002 through November 2004. Prior to that, Mr. Cataldo served as the Chief Executive Officer and Chairman of the Board of Directors of Miracle Entertainment, Inc., a Canadian film production company, from May 1999 through May 2002 where he was the executive producer or producer of several motion pictures. From August 1995 to December 1998, Mr. Cataldo served as President and Chairman of the Board of Senetek, PLC (OTC BB:SNTKY), a publicly traded biotechnology company involved in age-related therapies.



■ VALUE DRIVERS

□ Prevention – Nutraceuticals market

- Powerful anti-oxidant supplement
 - Ergothioneine

□ Treatment

- Therapeutics
 - Anti-Inflammatory (BXT-51072) (ALT-2074)
 - Lipid Soluble Anti-Oxidants (LSA)
 - Superoxide Dismutase (SOD)
 - Ergo Analogs (L-Ergo)



■ TARGET MARKETS

□ **Nutraceuticals Market**

- Global Raw Nutraceutical Materials Market
 - \$500 million to \$1.5 billion in 2004
- Vitamins and Supplements Market (U.S.)
 - \$17.8 billion in 2003
- Market Growth of 5% per year since 2000
- Growth Drivers:
 - Aging population
 - Increased health awareness




■ PIPELINE

□ Ergothioneine Analogs (L-Ergo™)

- Ergothioneine - naturally occurring antioxidant in body tissues subject to oxidative stress (eye lens, liver and red blood cells)
- “Discovery of the Ergothioneine Transporter”; D. Grundemann et al; Proc.Natl.Aca.Sci., USA
2005 April 5; 102 (14): 5256-5261
- Highly potent - scavenges reactive oxygen species:
1unit Ergo = 7,000 units Trolox (Vitamin E)
- Potential applications: cell preservation, program cell death, nutritional supplements
- Manufacturing patents


■ PIPELINE

□ L-Ergo™ – Cell Preservation



■ PIPELINE

□ L-Ergo™ – Cell Preservation





■ STRATEGY

- L-Ergothioneine sales-veterinary and human
 - Potential collaborators include:
 - Manor Marketing Inc.
- Increase sales of existing products
- Achieve positive cash flow
- Position OXIS as dominant player in diseases associated with oxidative stress/inflammation



■ PIPELINE

□ **Lipid Soluble Antioxidants (LSA)**

- Mimic body's natural cell membrane-protecting antioxidant Vitamin E but 20x to 40x more potent
- Potential applications: neurodegenerative and cardiovascular diseases

□ **Superoxide Dismutase (SOD)**

- Palosein: Treatment of acute and chronic inflammatory conditions in animals
- Orgotein: Prevention of radiation fibrosis and scarring in radiation treatment patients; marketed in Europe by Tedec/Meiji



Additional Oxis Opportunities



■ PIPELINE

□ **Anti-Inflammatory BXT-51072 (ALT-2074)**

- Glutathione Peroxidase (GPx) Mimetic
- Cardiovascular indications licensed to Alteon (ALT-2074)
 - License fees for milestones in excess of \$21 million
- In Phase 2 trials
 - Gastrointestinal indications; Phase 2 ulcerative colitis study completed by OXIS
 - Novel Anti-Inflammatory mechanism of action ⁽¹⁾
 - Metabolizes Lipid Peroxides that cause inflammation
 - Treats acute ischemic injury

(1) Source: Alteon company presentation



■ PIPELINE


□ Anti-Inflammatory BXT-51072 (ALT-2074)

- Orally Dosed Phase 2 Small Molecule
- >50 patients in Phase 1 and 2 - anti-inflammatory indication
- Novel Anti-Inflammatory Mechanism of Action
 - Glutathione Peroxidase (GPx) Mimetic
 - Metabolizes Lipid Peroxides
 - Decreases over-expression of key cytokines and messengers
- Rapid Action
- Restores Function
 - Acute, ischemia-reperfusion protection *without* hemodynamic instability

■ PIPELINE

□ Anti-Inflammatory BXT-51072 (ALT-2074)

- Haptoglobin typing predicts clinical event rate



Source: Alteon company presentation



- LICENSING DEAL with ALTEON (AMEX: ALT)

- Agreement expands scope of previous license to develop, manufacture and market ALT-2074 in all indications.
- OXIS will receive an upfront license fee of \$500,000 over a six month period as well as development milestone payments and royalties from the sales of products developed from the license.
- Alteon has agreed to invest \$500,000 in OXIS common stock, at a per-share price equal to 125% of the quoted price of OXIS common stock immediately prior to the date of investment, and no less than \$0.24 per share.





OXIS International